Cancer Research KI list of basic cancer research PIs across KI
Cancer Research KI list of basic cancer research PIs across KI
| First Name | Surname | KI email | Department | Please provide a brief description of your cancer research. | Group KI website URL |
|---|---|---|---|---|---|
| Adnane | Achour | adnane.achour@ki.se | Department of Medicine, Solna (MedS) | Determination of the molecular bases underlying increased T cell and/or NK cell responses towards tumor-associated epitopes. Combination of functional in vivo and in vitro immunology with structural biology and biophysical approaches. | https://www.scilifelab.se/researchers/adnane-achour/ |
| Agneta | Åkesson | Agneta.Akesson@ki.se | Institute of Environmental Medicine (IMM) | Diet and environmental contaminants and risk of cancer target this mechanism to arrest cancer cell growth | https://ki.se/en/imm/unit-of-cardiovascular-and-nutritional-epidemiology |
| Björn | Andersson | bjorn.andersson@ki.se | Department of Cell and Molecular Biology (CMB) | The use of virus metagenomics to study viruses in paediatric and other cancers. | https://ki.se/en/cmb/bjorn-anderssons-group |
| Elias | Arnér | elias.arner@ki.se | Department of Medical Biochemistry and Biophysics (MBB) | We study selenoproteins, containing the rare amino acid selenocysteine, with a special focus on isoenzymes of thioredoxin reductase and glutathione peroxidase. These enzymes are involved in antioxidant defence and reductive enzyme systems modulating intracellular signaling pathways, and are also promising novel anticancer drug targets. | https://ki.se/en/mbb/research-division-of-biochemistry |
| Per | Arvidsson | per.arvidsson@ki.se | Department of Medical Biochemistry and Biophysics (MBB) | The SciLifeLab Drug Discovery & Development infrastructure is supporting researcher from all over Sweden with their translational research projects. We have a strong track-record of delivering novel cancer therapies that are now progressing to clinical trials. | https://www.scilifelab.se/units/ddd-platform/ |
| Laura | Baranello | laura.baranello@ki.se | Department of Cell and Molecular Biology (CMB) | Inhibitors of DNA Topoisomerases are mainstays of anticancer therapy. While they have proven effective, the toxicity of current topoisomerase drugs limits their use in clinic. My research program aims to define the mechanism of topoisomerases, to understand how topoisomerases are regulated and search for novel drugs that target these regulatory mechanisms. My group has recently discovered that the oncoprotein MYC stimulates the activity of topoisomerases to boost cellular growth. We aim to block this mechanism to arrest MYC-driven tumors. We tackle this goal by using genomic approaches, biochemistry, microscopy and drug screens. | https://ki.se/en/cmb/laura-baranellos-group |
| Dzevad | Belkic | dzevad.belkic@ki.se | Department of Oncology-Pathology (Onk-Pat) | ||
| Christer | Betsholtz | christer.betsholtz@ki.se | Department of Medicine, Huddinge (MedH) | ||
| Magda | Bienko | magda.bienko@ki.se | Department of Microbiology, Tumor and Cell Biology (MTC) | I work on perturbations to the 3D genome structure that occur in cancer cells and study how they affect gene expression. | https://bienkocrosettolabs.org/ |
| Camilla | Björkegren | camilla.bjorkegren@ki.se | Department of Cell and Molecular Biology (CMB) | The principal aim of our research is to elucidate how cells maintain chromosome stability. The cancer relevance comes from the well established correlation between chromosomal instability and cancer, and incorrect chromosome replication, repair and segregation are known to promote tumor development. | https://ki.se/en/cmb/camilla-bjorkegrens-group |
| Ingemar | Björkhem | ingemar.bjorkhem@ki.se | Department of Laboratory Medicine (LabMed) | ||
| Mikael | Björnstedt | mikael.bjornstedt@ki.se | Department of Laboratory Medicine (LabMed) | ||
| Lennart | Blomqvist | lennart.k.blomqvist@ki.se | Department of Molecular Medicine and Surgery (MMK) | ||
| Yihai | Cao | yihai.cao@ki.se | Department of Microbiology, Tumor and Cell Biology (MTC) | ||
| Benedict | Chambers | Benedict.Chambers@ki.se | Department of Medicine, Huddinge (MedH) | My research examines how the innate immune system can affect adaptive immune responses | |
| Nicola | Crosetto | nicola.crosetto@ki.se | Department of Microbiology, Tumor and Cell Biology (MTC) | Our primary focus in on developing new tools to study intratumor heterogeneity and genomic alterations in cancer. | |
| Joakim | Dahlin | joakim.dahlin@ki.se | Department of Medicine, Solna (MedS) | We chart basophil and mast cell differentiation in hematologic neoplasms. | |
| Nico | Dantuma | nico.dantuma@ki.se | Department of Cell and Molecular Biology (CMB) | Exploring intracellular protein degradation, in particular the ubiquitin-proteasome system, as therapeutic target. | https://ki.se/en/cmb/nico-dantumas-group |
| Teresita | Díaz De Ståhl | teresita.diaz.de.stahl@ki.se | Department of Oncology-Pathology (Onk-Pat) | ||
| Kristian | Dreij | Kristian.Drej@ki.se | Institute of Environmental Medicine (IMM) | ||
| Stefan | Einhorn | stefan.einhorn@ki.se | Department of Oncology-Pathology (Onk-Pat) | ||
| Karl | Ekwall | karl.ekwall@ki.se | Department of Biosciences and Nutrition (BioNut) | ||
| Simon | Elsässer | simon.elsasser@ki.se | Department of Medical Biochemistry and Biophysics (MBB) | Cancer epigenomics, oncogenic histone mutants,G4 structures, ssDNA and SSB mapping | https://elsaesserlab.wordpress.com |
| Maria | Eriksson | maria.eriksson.2@ki.se | Department of Biosciences and Nutrition (BioNut) | We analyze age-related somatic mutagenesis and study mutational signatures and clonal propagation of individual mutations in apparantly healthy tissue | https://ki.se/en/bionut/genetic-mechanisms-of-ageing-maria-eriksson |
| Ingemar | Ernberg | ingemar.ernberg@ki.se | Department of Microbiology, Tumor and Cell Biology (MTC) | How infections increase the risk of human cancer. Initiation of proliferation, migration/invasion after virus infection and metabolic reprogramming upon tumor virus infection | https://ki.se/en/mtc/ingemar-ernberg-group |
| Alexander | Espinosa | alexander.espinosa@ki.se | Department of Medicine, Solna (MedS) | ||
| Bengt | Fadeel | bengt.fadeel@ki.se | Institute of Environmental Medicine (IMM) | ||
| Marianne | Farnebo | Marianne.farnebo@ki.se | Department of Cell and Molecular Biology (CMB) | RNA-mediated DNA repair in cancer | https://ki.se/en/cmb/marianne-farnebos-group |
| Oscar | Fernandez-Capetillo | oscar.fernandez-capetillo@ki.se | Department of Medical Biochemistry and Biophysics (MBB) | I try to combine mouse models, cell biology and genetic and chemical screens for developing new therapies. | https://ki.se/en/mbb/oscar-fernandez-capetillo-group |
| Jonas | Frisén | jonas.frisen@ki.se | Department of Cell and Molecular Biology (CMB) | We study cell generation in health and disease, including cancer. We study several organ systems in mice and humans. | https://ki.se/en/cmb/jonas-frisens-group |
| Jonas | Fuxe | jonas.fuxe@ki.se | Department of Laboratory Medicine (LabMed) | The overall aim of our research program is to elucidate mechanisms involved in cancer metastasis and determine whether these can be used as novel diagnostic tools and/or therapeutic targets. We are specifically interested in exploring links between inflammation and tumor cell plasticity. | https://ki.se/en/labmed/jonas-fuxe-group |
| Susanne | Gabrielsson | susanne.gabrielsson@ki.se | Department of Medicine, Solna (MedS) | The role of cancer-derived exosomes in disease and how to use exosomes for therapy. | |
| Guillem | Genové | guillem.genove@ki.se | Department of Medicine, Huddinge (MedH) | To understand the role of pericytes in tumors and their role in immune cell recruitment | |
| Carmen | Gerlach | carmen.gerlach@ki.se | Department of Medicine, Solna (MedS) | CD8+ T cell responses against tumor-expressed antigens | https://ki.se/en/meds/research-group-carmen-gerlach |
| Leonard | Girnita | Leonard.Girnita@ki.se | Department of Oncology-Pathology (Onk-Pat) | "Receptor pathology" lab, performing translational research by investigating the molecular properties and regulatory mechanisms that control the function of plasma membrane receptors under normal and pathological circumstances. The final goal is to determine potential utility of the signaling complexes involved in the RTKs/GPCRs cross talk as biomarkers or molecular targets in cancer. | https://ki.se/en/onkpat/leonard-girnitas-group |
| Anita | Göndör | anita.gondor@ki.se | Department of Oncology-Pathology (Onk-Pat) | ||
| Roland | Grafström | roland.grafstrom@ki.se | Institute of Environmental Medicine (IMM) | ||
| Nina | Gustafsson | nina.gustafsson@ki.se | Department of Oncology-Pathology (Onk-Pat) | Our research is focused on understanding how altered metabolism can regulate the DNA repair capacity of cancer cells with the goal to translate our findings into novel treatments for cancer patients. | https://ki.se/en/onkpat/research-team-nina-gustafsson |
| Jean | Hausser | jean.hausser@ki.se | Department of Cell and Molecular Biology (CMB) | We are a research lab of 10 scientists, from experimental biology to data science to theoretical physics. Our long-term vision is to discover equations of tumor heterogeneity and tumor immunology in order to turn oncology into an engineering discipline. | https://www.hausserlab.org |
| Thomas | Helleday | thomas.helleday@scilifelab.se | Department of Oncology-Pathology (Onk-Pat) | We study the basic mechanisms of DNA damage response and repair and identify novel anti-cancer treatment concepts that can be exploited for cancer treatments. We purify protein targets, develop assays and first-in-class small molecule inhibitors that we take into first-in-man clinical trials. | https://ki.se/en/onkpat/thomas-helledays-group |
| Rainer | Heuchel | rainer.heuchel@ki.se | Department of Clinical Science, Intervention and Technology (ClinTec) | We investigate the question of extreme therapy resistance in pancreatic cancer by tumor stroma crosstalk interrogation in 3D cell culture models and genetically engineered mouse models. | |
| Björn | Högberg | bjorn.hogberg@ki.se | Department of Medical Biochemistry and Biophysics (MBB) | ||
| Johan | Högberg | johan.hogberg@ki.se | Institute of Environmental Medicine (IMM) | ||
| Lars | Holmgren | lars.holmgren@ki.se | Department of Oncology-Pathology (Onk-Pat) | We study the role of mechanotransduction in tumor cell invasion. We are screening for compounds that inhibit this process | |
| Christer | Höög | christer.hoog@ki.se | Department of Cell and Molecular Biology (CMB) | Segregation of chromosomes at the metaphase/anaphase stage of the cell cycle during mitosis and meiosis. | |
| Hans | Jacobsson | hans.jacobsson@ki.se | Department of Molecular Medicine and Surgery (MMK) | ||
| Lars | Jakobsson | lars.jakobsson@ki.se | Department of Medical Biochemistry and Biophysics (MBB) | Properties of the tumour vasculature, and vascular targeting. Progression from vascular anomalies to angiosarcoma involving TGFb, VEGF and mTORC1 signalling | http://ki.se/en/mbb/lars-jakobsson-group |
| Per-Johan | Jakobsson | per-johan.jakobsson@ki.se | Department of Medicine, Solna (MedS) | Role of prostaglandin E2 and microsomal prostaglandin E synthase inhibition in cancer | https://ki.se/en/meds/research-group-per-johan-jakobsson |
| Randall | Johnson | randall.johnson@ki.se | Department of Cell and Molecular Biology (CMB) | Hypoxia and its role in tumor pathology and immunotherapy | |
| Dimitris | Kanellis | dimitris.kanellis@ki.se | Department of Medical Biochemistry and Biophysics (MBB) | Working with cell line models to unravel cancer vulnerabilities related to ribosome biogenesis and protein translation. | https://ki.se/en/mbb/jiri-bartek-group |
| Maria | Kasper | maria.kasper@ki.se | Department of Cell and Molecular Biology (CMB) | We investigate i) inter- and intra-tumoral heterogeneity at single-cell resolution (scRNAseq/smFISH), ii) how wounding, stromal micro-niches, and immune-cell signaling promote skin cancer formation, and iii) how to redirect a tumor-cell fate into a developmental program. | http://kasperlab.org/ |
| Claudia | Kutter | claudia.kutter@ki.se | Department of Microbiology, Tumor and Cell Biology (MTC) | We identify and characterize cancer-specific connections between protein-coding and noncoding RNAs. Our goal is to gain mechanistic insight into the transcriptional and posttranscriptional regulation of RNA when cells progress from a healthy to a malignant state. | https://ki.se/en/mtc/kutter-group-regulatory-transcriptions |
| Sonia | Lain | sonia.lain@ki.se | Department of Microbiology, Tumor and Cell Biology (MTC) | We have discovered potent and specific small molecule inhibitors that are currently being developed for the treatment of cancer. At present we are working on identifying agents to remove/inhibit enzymes that accumulate in plasma during ageing and disease, including metastatic cancer. | |
| Michael | Landreh | michael.landreh@ki.se | Department of Microbiology, Tumor and Cell Biology (MTC) | ||
| David | Lane | david.lane@ki.se | Department of Microbiology, Tumor and Cell Biology (MTC) | ||
| Nils-Göran | Larsson | nils-goran.larsson@ki.se | Department of Medical Biochemistry and Biophysics (MBB) | Cancer cell metabolism and the dependency on mitochondria. The Warburg effect. | https://molmet.ki.se/nils-goran-larsson |
| Lars-Gunnar | Larsson | lars-gunnar.larsson@ki.se | Department of Microbiology, Tumor and Cell Biology (MTC) | ||
| Ola | Larsson | ola.larsson@ki.se | Department of Oncology-Pathology (Onk-Pat) | Studies of how mRNA translation is dysregulated in cancer. Identification of potential avenues for treatment by targeting dysregulated mRNA translation. | https://ki.se/en/onkpat/ola-larssons-group |
| Olle | Larsson | olle.larsson@ki.se | Department of Oncology-Pathology (Onk-Pat) | ||
| Kaisa | Lehti | kaisa.lehti@ki.se | Department of Microbiology, Tumor and Cell Biology (MTC) | ||
| Bennie | Lemmens | bennie.lemmens@ki.se | Department of Medical Biochemistry and Biophysics (MBB) | The Lemmens group develops and combines innovative protein depletion methods with cutting-edge imaging techniques to study how, when and where DNA replication starts. In parallel, we use various CRISPR-based technologies to discover new factors driving cell proliferation and cancer drug resistance. | https://ki.se/en/mbb/bennie-lemmens-group |
| Arne | Lindqvist | arne.lindqvist@ki.se | Department of Cell and Molecular Biology (CMB) | Cell fate choice after DNA damage, primarily whether senescence or mitosis occurs. In particular DNA damage that appears during S/G2/M phases of the cell cycle, including replication stress. | https://ki.se/en/cmb/arne-lindqvists-group |
| Sten | Linnarsson | sten.linnarsson@ki.se | Department of Medical Biochemistry and Biophysics (MBB) | ||
| Sidinh | Luc | sidinh.luc@ki.se | Department of Medicine, Huddinge (MedH) | Our research program primarily focuses on hematopoietic stem cells in normal development. Detailed knowledge of blood formation and the different stem cell types will increase our fundamental understanding of how hematologic diseases may develop and how they may be treated. | https://ki.se/en/medh/sidinh-luc-group-properties-of-blood-stem-cells-a… |
| Weng-Onn | Lui | weng-onn.lui@ki.se | Department of Oncology-Pathology (Onk-Pat) | Basic and translational research in Merkel cell carcinoma | |
| Gerald | McInerney | gerald.mcinerney@ki.se | Department of Microbiology, Tumor and Cell Biology (MTC) | ||
| Victoria | Menendez Benito | victoria.menendez.benito@ki.se | Department of Biosciences and Nutrition (BioNut) | ||
| Ralf | Morgenstern | ralf.morgenstern@ki.se | Institute of Environmental Medicine (IMM) | ||
| Jonas | Muhr | jonas.muhr@ki.se | Department of Cell and Molecular Biology (CMB) | examining cancer stemness regulating pathways | |
| Gunnar | Nilsson | gunnar.p.nilsson@ki.se | Department of Medicine, Solna (MedS) | Systemic mastocytosis is characterized by aberrant mast ells with D816V KIT mutation. Patients have mediator symptoms and/or organ failure due to mast cell infiltration. | https://ki.se/en/meds/gunnar-nilsson-group |
| Roland | Nilsson | roland.nilsson@ki.se | Department of Medicine, Solna (MedS) | My group studies cancer metabolism, particularly one-carbon and methionine metabolism, striving to identify new drug targets. We use large-scale metabolomics techniques and stable isotope tracing to measure metabolism. | https://ki.se/en/meds/research-group-roland-nilsson |
| Helin | Norberg | erik.norberg@ki.se | Department of Physiology and Pharmacology (Fyfa) | We try to understand how and why cancer metabolism is distinct from normal cells. | https://ki.se/en/fyfa/the-erik-norberg-lab-cellular-metabolism |
| Magnus | Nordenskjöld | magnus.nordenskjold@ki.se | Department of Molecular Medicine and Surgery (MMK) | ||
| Pär | Nordlund | par.nordlund@ki.se | Department of Oncology-Pathology (Onk-Pat) | ||
| Rolf | Ohlsson | rolf.ohlsson@ki.se | Department of Oncology-Pathology (Onk-Pat) | ||
| Laura | Orellana | laura.orellana@ki.se | Department of Oncology-Pathology (Onk-Pat) | We explore the molecular basis of cancer at the deepest, atomic level, in terms of protein structures and how mutations alter conformation and function. | https://ki.se/en/onkpat/research-team-laura-orellana-protein-dynamics-a… |
| Päivi | Östling | paivi.ostling@ki.se | Department of Oncology-Pathology (Onk-Pat) | My research is on precision cancer medicine in agressive bladder cancer. The aim is to link spatial tissue maps with drug sensitivity and molecular profiles to understand treatment responses. | https://ki.se/en/onkpat/olli-kallioniemis-group |
| Arne | Östman | arne.ostman@ki.se | Department of Oncology-Pathology (Onk-Pat) | The research aims at a better understanding of the paracrine interplay in the tumor microenvironment between malignant cells, fibroblasts, vascular cells and immune cells. Studies combine profiling of clinical samples with experimental studies and drug screening. | https://ki.se/en/onkpat/research-team-arne-ostman |
| Brent | Page | brent.page@ki.se | Department of Oncology-Pathology (Onk-Pat) | We use state of the art chemical biology and medicinal chemistry techniques to identify novel cancer therapeutic agents. | |
| Qiang | Pan-Hammarström | Qiang.Pan-Hammarstrom@ki.se | Department of Biosciences and Nutrition (BioNut) | ||
| Theocharis | Panaretakis | theoharis.panaretakis@ki.se | Institute of Environmental Medicine (IMM) | ||
| Manuel | Patarroyo | manuel.patarroyo@ki.se | Department of Microbiology, Tumor and Cell Biology (MTC) | To identify transcription factors responsible for tumor aggressiveness.To identify and develop antagonists of malignancy-associated transcription factors as a novel therapeutic strategy against cancer. | https://ki.se/en/mtc/marie-arsenian-henriksson-group |
| Yudi | Pawitan | yudi.pawitan@ki.se | Department of Medical Epidemiology and Biostatistics (MEB) | ||
| Vicent | Pelechano | vicente.pelechano.garcia@ki.se | Department of Microbiology, Tumor and Cell Biology (MTC) | We focus on understanding how single-cell variability, cellular plasticity and transcriptional memory contribute to the appearance of drug-tolerant cancer persister cells. We also develop novel clinical genomic tools for cancer patient stratification. | https://ki.se/en/mtc/vicent-pelechano-group |
| Teresa | Pereira | teresa.pereira@ki.se | Department of Molecular Medicine and Surgery (MMK) | ||
| Katja | Petzold | katja.petzold@ki.se | Department of Medical Biochemistry and Biophysics (MBB) | We work on RNA biophysics and structural biology, with focus on microRNA, ribosomes, viral RNA & drug development | http://petzoldlab.com/ |
| Federico | Pietrocola | federico.pietrocola@ki.se | Department of Biosciences and Nutrition (BioNut) | We focus on the effect of stromal senescence on the progression and response to therapy in murine models of NSCLC | https://ki.se/en/bionut/federico-pietrocolas-group |
| Andor | Pivarcsi | andor.pivarcsi@ki.se | Department of Medicine, Solna (MedS) | I study the role of non-coding RNAs in cutaneous carcinogenesis. | |
| Agneta | Rannug | agneta.rannug@ki.se | Institute of Environmental Medicine (IMM) | ||
| Christian | Riedel | christian.riedel@ki.se | Department of Biosciences and Nutrition (BioNut) | We are interested in a) aneuploidy (one of the hallmarks of cancer) and b) the communication between cancer cells and their surroundings. | https://ki.se/en/bionut/ageing-basic-mechanisms-and-interventions-chris… |
| Charlotte | Rolny | charlotte.rolny@ki.se | Department of Oncology-Pathology (Onk-Pat) | ||
| Sean | Rudd | sean.rudd@ki.se | Department of Oncology-Pathology (Onk-Pat) | The Rudd lab investigates metabolic pathways operating inside cancer cells and how these pathways support malignant disease. We are particularly focused upon the metabolic interplay between the DNA precursor pool and the DNA molecule, a relationship that is fundamental to cancer biology, underpinning key aspects of oncogenesis together with therapy resistance. | https://ki.se/en/onkpat/research-team-sean-rudd |
| Rickard | Sandberg | rickard.sandberg@ki.se | Department of Cell and Molecular Biology (CMB) | ||
| Olle | Sangfelt | olle.sangfelt@ki.se | Department of Cell and Molecular Biology (CMB) | We study SCF ubiquitin ligases targeting critical oncoproteins for degradation to identify novel cancer vulnerabilities. The research is focused on the molecular function and regulatory characteristics of SCF ligases regulating replication stress, DNA repair and immune evasion pathways. | https://ki.se/en/cmb/olle-sangfelts-group |
| Susanne | Schlisio | susanne.schlisio@ki.se | Department of Microbiology, Tumor and Cell Biology (MTC) | Why are advanced cancers eventually acquiring resistance to targeted therapies and relapse? What are the causes of clinical heterogeneity and outcome in high-risk childhood neuroblastoma.How do we cope with oxygen deprivation (hypoxia) in health and disease? | https://ki.se/en/mtc/schlisio-lab |
| Herwig | Schüler | herwig.schuler@ki.se | Department of Biosciences and Nutrition (BioNut) | Pre-clinical development of PARP inhibitors | https://ki.se/en/bionut/protein-adp-ribosylation-herwig-schuler |
| Gunnar | Schulte | gunnar.schulte@ki.se | Department of Physiology and Pharmacology (Fyfa) | We aim to understand activation mechanisms of FZDs, the main WNT receptors. Thereby we promote a mechanism-based and structure-guided drug discovery approach leading to FZD-targeting small molecules with therapeutic potential as anticancer drugs. | https://ki.se/en/fyfa/schulte-lab |
| Galina | Selivanova | galina.selivanova@ki.se | Department of Microbiology, Tumor and Cell Biology (MTC) | My research is focused on p53 biology and the development of p53-targeting therapies to restore its tumour suppression function. I am interested in the role of p53 in immune response, epigenetics and its interaction with microbiome. | https://ki.se/en/mtc/galina-selivanova-group |
| Kirsty | Spalding | kirsty.spalding@ki.se | Department of Cell and Molecular Biology (CMB) | We are interested in how mature human fat cells promote cancer cell progression and metastasis | spaldinglab.org |
| Peter | Strang | peter.strang@ki.se | Department of Oncology-Pathology (Onk-Pat) | ||
| Lena | Ström | Lena.Strom@ki.se | Department of Cell and Molecular Biology (CMB) | Importance of chromosome organization and DNA repair for genome integrity. | https://ki.se/en/cmb/lena-stroms-group |
| Staffan | Strömblad | staffan.stromblad@ki.se | Department of Biosciences and Nutrition (BioNut) | We study cell-matrix interactions and its down-stream mechanotransduction signaling and responses and how these affect key cellular processes of cancer cells. We use advanced light-microscopy and various in vitro and in vivo models and also analyze patient data and material. | https://ki.se/en/bionut/cell-biology-of-cancer-staffan-stromblad-0 |
| Peter | Svensson | peter.svensson@ki.se | Department of Biosciences and Nutrition (BioNut) | At least 20% of cancers have infectious origins. HIV is not an oncogenic virus, but we study how it acts as an indirect carcinogen through chronic immune stimulation and specific host-pathogen interactions. | https://ki.se/en/bionut/mechanisms-behind-hiv-1-latency-and-rebound-pet… |
| Laszlo | Szekely | laszlo.szekely@ki.se | Department of Laboratory Medicine (LabMed) | High throughput drug sensitivity measurement of primary human tumors | |
| Jussi | Taipale | jussi.taipale@ki.se | Department of Medical Biochemistry and Biophysics (MBB) | ||
| Ana | Teixeira | ana.teixeira@ki.se | Department of Medical Biochemistry and Biophysics (MBB) | We investigate how the organisation of membrane proteins at the nanoscale affects their functions in normal and cancer cells. | |
| Emma | Tham | emma.tham@ki.se | Department of Molecular Medicine and Surgery (MMK) | (1) Hereditary Cancer – genetic cause of hereditary cancer, genetic risk factors and optimal surveillance in rare cancer syndromes(2) Cell-free tumour DNA (liquid biopsy) in diagnosis, prognosis and follow-up in adult and paediatric cancer patients | https://ki.se/en/mmk/clinical-genetics |
| Eckardt | Treuter | eckardt.treuter@ki.se | Department of Biosciences and Nutrition (BioNut) | ||
| Per | Uhlén | per.uhlen@ki.se | Department of Medical Biochemistry and Biophysics (MBB) | Our group studies the intratumoral heterogeneity in various types of human cancer. We explore cancer stem cells, cell niches, and the tumor vasculature in intact tumor samples. | http://www.uhlenlab.org |
| Julian | Walfridsson | julian.walfridsson@ki.se | Department of Medicine, Huddinge (MedH) | ||
| Ulrika | Warpman Berglund | ulrika.berglund@ki.se | Department of Oncology-Pathology (Onk-Pat) | The research aims to i) purifying and targeting proteins in DNA repair and metabolism, ii) use probes and genetic tools to increase basic knowledge around target proteins and iii) translating basic research findings into new treatments tested in clinic | https://ki.se/en/onkpat/thomas-helledays-group |
| Anna | Wedell | anna.wedell@ki.se | Department of Molecular Medicine and Surgery (MMK) | ||
| Margareta | Wilhelm | margareta.wilhelm@ki.se | Department of Microbiology, Tumor and Cell Biology (MTC) | Our aim is to understand mechanisms regulating cancer and how the continuous cross talk between tumor cells, the surrounding stroma and infiltrating immune cells control tumor development. We use reprogramming techniques to generate disease-relevant stem cell models that mimic the disease and help uncover mechanisms that turn healthy cells into cancer cells and are used to uncover novel targets for developing future therapies. | https://ki.se/en/mtc/margareta-wilhelm-group |
| Klas | Wiman | klas.wiman@ki.se | Department of Oncology-Pathology (Onk-Pat) | Tumor biology, tumor suppressor genes, p53, cell death, cancer drug discovery, APR-246, clinical trials | https://ki.se/en/onkpat/klas-g-wimans-group |
| Dawei | Xu | Dawei.Xu@ki.se | Department of Medicine, Solna (MedS) | Telomerase activation mechanisms and roles in cancer. | |
| Ning | Xu Landén | ning.xu@ki.se | Department of Medicine, Solna (MedS) | Our study aimsto understand the pathological mechanisms underlying the late on-set adverse effects, in particular, the impaired wound repair after radiation therapy. | https://ki.se/en/meds/research-group-ning-xu-landen-skin-wound-healing |
| Joanna | Zawacka-Pankau | Joanna.Zawacka-Pankau@ki.se | Department of Medicine, Huddinge (MedH) | Drug repurposing for improved therapy in TP53 mutant cancers. | |
| Boris | Zhivotovsky | boris.zhivotovsky@ki.se | Institute of Environmental Medicine (IMM) | Cross-take between various cell death mechanisms and its importance for tumor cells elimination | |
| Roman | Zubarev | roman.zubarev@ki.se | Department of Medical Biochemistry and Biophysics (MBB) | Using mass-spectrometry-based proteomics, we investigate the drug targets and mechanisms of action, as well as ways to overcome resistance of cancer cells to treatment | http://ki.se/en/mbb/roman-zubarev-group |
| Martin | Bergö | Martin.Bergo@ki.se | Department of Biosciences and Nutrition (BioNut) | Basic and translational cancer research on molecular mechanisms of tumor initiation, progression, and metastasis | https://ki.se/en/bionut/cancer-rapid-ageing-and-nutrition-martin-bergo |